The p53 gene was examined in primary lymphoblasts of 25 pediatric patients with acute lymphoblastic leukemia by the RNase protection assay and by single strand conformation polymorphism analysis in 23 of 25 cases. p53 mutations were found to occur, but at a low frequency (4 of 25). While all four mutations were identified by single strand conformation polymorphism, the comparative sensitivity of RNase protection was 50% (2 of 4). Heterozygosity was retained at mutated codons in 3 of 4 cases. One pedigree was consistent with the Li-Fraumeni syndrome, and bone marrow from both diagnosis and remission indicated a germline G to T transversion at codon 272 (valine to leucine). Although members of another family were affected with leukemia, a 2-bp deletion in exon 6 was nonhereditary. The other two nonhereditary p53 mutations included a T to G transversion at codon 270 (phenylalanine to cysteine) and a G to C transversion at codon 248 (arginine to proline). These data support the role of both hereditary and acquired p53 mutations in the pathogenesis and/or progression of some cases of childhood acute lymphoblastic leukemia. (J. Clin. Invest. 1992. 
Introduction
After the discovery of the 8; 14 translocation and the consequent activation of the c-myc gene in Burkitt's lymphoma (1) , studies ofthe molecular basis ofchildhood acute lymphoblastic leukemia (ALL)' have concentrated upon searching for potential dominant oncogenes at breakpoint regions of chromosomal translocations (2) . In solid tumors of both children and adults, retinoblastoma being the paradigm, an additional focus has been the identification of genes of a different class, which function in their wild-type form as recessive oncogenes or tu-1. Abbreviations used in this paper: ALL, acute lymphoblastic leukemia; BM, bone marrow; CML, chronic myelogenous leukemia; ORF, open reading frame; PB, peripheral blood; PCR, polymerase chain reaction; SSCP, single strand conformation polymorphism.
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Volume 89, February 1992, 640-647 mor suppressor genes (3) . One such recessive oncogene is p53 (4) (5) (6) (7) (8) (9) (10) (11) (12) , located on chromosome 17 at band p13.1 (13, 14) . Inactivation of the human p53 gene, whether by gross structural change, homozygous deletion, or point mutation, has since been implicated in the pathogenesis oflung, breast, colon, brain, and liver cancers, chronic myelogenous leukemia (CML) and childhood osteogenic and rhabdomyosarcomas (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Moreover , recent studies have demonstrated the presence of germline p53 mutations in Li-Fraumeni pedigrees affected with breast cancers, sarcomas, and brain tumors (27, 28) . The observation of Li-Fraumeni syndrome-type cancers, including lymphomas, in transgenic mice overexpressing a mutant p53 has suggested a potential role ofp53 inactivation in the pathogenesis ofhuman lymphoid malignancies as well (29) . Since acute leukemias are considered component tumors ofthe Li-Fraumeni syndrome, we undertook to study the p53 gene in childhood ALL.
Methods
Sample collection. Materials were collected per protocol or as part of standard care. Lymphoblasts from 80 children with B cell precursor ALL, 21 with T cell ALL, and three infants, aged 0-21 yr at diagnosis, were obtained and characterized as previously described (30, 31) . Sampling times were at diagnosis, at bone marrow (BM) relapse, or at failure of induction chemotherapy. BM collected during remission was also available in one case. Cytogenetic analysis was by standard methods (32) . DNA and RNA preparation and Southern analysis. High molecular weight DNA and total cellular RNA were isolated as described (30, 31 Fig. 1 ).
Characterization of abnormalities suggested by screening. RNase protection abnormalities were verified by cDNA sequencing. Firststrand cDNA was synthesized using 5 ,ug of total cellular RNA and a p53-specific primer, followed by PCR amplification of the entire p53 ORF (15) . PCR products were cleaved with EcoRI, agarose gel-purified by the Geneclean method (Bio 101, La Jolla, CA), and ligated into the EcoRI site ofpGEM-7Zf+ (Promega Corp., Madison, WI) for transformation of DH5a cells (Bethesda Research Laboratories). The entire p53 ORF of individual cDNA subclones was sequenced using Sequenase Version 2.0 (U.S. Biochemical Corp., Cleveland, OH), SP6 and T7 sequencing primers, and four sense oligonucleotides which have been described (15) . Mutations were confirmed by sequencing the appropriate portion of the ORF in the opposite direction.
Mutations were also confirmed by restriction enzyme digestion of cDNA subclones if a restriction site was altered and by restriction enzyme digestion or direct sequencing ofgenomic DNA/PCR products. 1 ;ig of genomic DNA was PCR-amplified and 1/20 to 1/250 of these products was used as template in a second heminested PCR reaction for sequencing. 30 Characterization ofa p53 mutation in a case ofchildhood T cellALL. RNase protection assay ofperipheral blood (PB) lymphoblast mRNA of a child with relapsed T cell ALL (T-ALL Pt. 16) revealed relatively abundant p53 message and suggested the presence of both a normal allele and a point mutation on the other allele which localized to the PA fragment in a region 3' of the M probe (not shown). SSCP analysis also suggested a mutation which localized to exon 8 ( Fig. 1 ). cDNA sequencing of the p53 ORF revealed a point mutation (TTT to TGT, phenylalanine to cysteine) at codon 270, thus confirming the findings of both RNase protection and SSCP (Fig. 2 ). This mutation creates a novel PvuII restriction site, and PvuII digestion of a PCR-amplified fragment of lymphoblast genomic DNA and of additional cDNA subclones verified the presence of both mutant and wild-type alleles (not shown).
Characterization of two p53 abnormalities in a case of childhood B-cell precursor ALL. RNase protection assay of PB lymphoblast mRNA of a child with relapsed B cell precursor ALL (Pre-B ALL Pt.4) showed a relatively low level of p53 mRNA. The absence of mRNAs fully protected by either the PA or M probes suggested the absence of a normal allele. Protection of four fragments by the 3' PA probe whose sum length exceeded the size of complete protection suggested the presence of more than one mRNA (not shown). One abnormality was present in the region of the M probe overlapping PA and was more specifically localized to exon 6 by SSCP (Fig. 1) . The presence of two mRNA species, both with a 2-bp deletion at p53 codons 214/215 which would cause a frame shift and use of a premature TGA termination codon in exon 6 was confirmed by cDNA sequencing (Fig. 2) . Direct sequencing ofthis area in PCR-amplified lymphoblast genomic DNA revealed that only the mutant allele was present.
One cDNA subclone contained not only the codon 214/ 215 deletion, but also a 133-bp insertion at the precise junction of the unaltered 3' and 5' ends of exons 9 and 10, respectively (Fig. 2) . This cDNA insertion sequence matched that of se- consensus sequences at the exon 9/intron 9 boundary (donor: TCAGgtacta) and the intron 9/exon 10 boundary (acceptor: ctgcagATCC) and sequences flanking the 133-bp intron 9 insertion. (For genomic sequences surrounding this insertion, see legend to Fig. 2. ) These data corroborate all RNase protection fragments identified and are consistent with p53 allele loss and low-level transcription oftwo related, but different mRNA species by alternative splicing from a single mutant allele.
Characterization of a p53 mutation in a case of ALL of infancy. Although RNase protection assay of lymphoblast mRNA ofan infant with B cell precursor ALL at relapse (Infant ALL Pt.3) showed full-length protection with all three riboprobes (not shown), SSCP analysis of genomic DNA from the same sampling suggested both a normal allele and an abnormal allele with a mutation in exon 7 (Fig. 1) , which by direct sequencing was found to be a G to C transversion at p53 codon 248 (CGG to CCG, arginine to proline) (Fig. 2) . In contrast, repeated SSCP analyses of lymphoblast genomic DNA sampled at diagnosis revealed exon 7-containing PCR fragments of only the normal size, suggesting that the mutation had been acquired at some time during the course of therapy.
A germlinep53 mutation in childhood B cellprecursorALL. The leukemic cells of an adolescent male (Pre-B ALL Pt.80) showed a triploid karyotype. No p53 mutation was detected by the RNase protection assay (not shown), but SSCP analysis of BM lymphoblast genomic DNA suggested that a mutation in exon 8 was present at diagnosis (Fig. 1) . At least one normal sequence and a G to T transversion at p53 codon 272 (GTG to TTG, valine to leucine) were found by direct sequencing (Fig.  2) . Thus, heterozygosity appeared to be retained, although some contribution to the normal sequence by nonleukemic cells is possible. Both SSCP analysis and direct sequencing showed that mutant and normal alleles were also present in a remission BM sample where morphological examination showed no evidence ofdisease (Fig. 1) . These data indicate that the mutation at p53 codon 272 was germline and likely hereditary (c.f. subsection Family studies below).
Southern analysis ofpolymorphic regions. Southern analysis of the pBHP53, pMCT35. ----------mosome 17p allele loss in one case with evidence of mutation of the p53 gene where only the mutant p53 allele was identified (Pre-B ALL Pt. 4) and verify heterozygosity at chromosome 17p in two cases where both normal and mutant p53 alleles were found (Infant ALL Pt. 3 and Pre-B ALL Pt. 80). In the case of T-ALL Pt. 16, the leukemic cells showed one normal p53 sequence and an abnormal sequence with a mutation at p53 codon 270, yet homozygous patterns at all three polymorphic loci. Based upon the expected frequencies ofheterozygosity at these loci (49%, 38%, and 86%, respectively), the chance that all would be homozygous in the same individual is 4% (33) (34) (35) . Despite the small chance of this combination, and since both normal and mutant alleles were present, these findings are consistent with retention of both alleles which were by chance homozygous at each of the three 17p polymorphic loci. Family studies. Medical and family histories were available on 18 of the 25 patients studied by RNase protection and on the child whose lymphoblast DNA showed a novel EcoRI site. The younger brother ofthe patient with a germline mutation at p53 codon 272 was recently diagnosed with osteogenic sarcoma, and the mother of the patient and five maternal grandparents or their siblings were affected at ages as young as 30 years with lung and other cancers. This kindred may thus represent a Li-Fraumeni family (Fig. 3, top) . However, in the three other cases ofchildhood ALL analysis ofp53 sequence in parental genomic DNA indicated that the p53 mutations were nonhereditary (not shown). Despite the acquired nature of these mutations, the patient whose lymphoblasts contained a p53 codon 214/215 deletion had a brother and distant cousin with childhood acute leukemia and a family history of leukemia and breast, gastrointestinal, and prostate cancers over four generations of adults (Fig. 3, bottom) . The families of the other two children whose lymphoblasts contained p53 mutations were affected by cancer only during adulthood, and thus were not suggestive of the Li-Fraumeni syndrome. The families of 14 patients whose lymphoblast p53 genes were normal and of the patient-with a novel EcoRI restriction site were either unaffected by cancer (10 of 15), or affected only during adulthood (5 of 15). In addition, one child with normal lymphoblast p53 genes had a past history of Ewing's sarcoma, and another a history remote by 14 years of previous ALL.
Discussion
The impetus for this investigation of p53 mutations in childhood ALL, whether hereditary or acquired, was the reported finding that mice transgenic for a mutant p53 gene developed lymphoid tumors as well as other Li-Fraumeni syndrome cancers (29) . This syndrome of multiple primary cancers, which occur at an early age in either individuals or in families, was first described in 1969 (42) . Soft tissue sarcomas, bone, brain, and breast cancers, adrenal cortical carcinomas, and leukemias are considered component tumors of this syndrome in the human. In pedigrees with breast cancers, sarcomas, and brain tumors, the presence of germline p53 mutations in a region containing codons 245, 248, 252, and 258 has suggested that p53 may be the cancer susceptibility gene (27, 28) . The present study demonstrates that in childhood ALL, another component tumor, the p53 gene sometimes may be altered by small mutations which are either hereditary or acquired and which would lead to changes in predicted p53 peptides (Table I).
The lymphoblasts ofone child with relapsed T cell ALL and an acquired p53 mutation showed a T to G transversion at codon 270 that would result in amino acid substitution (phenylalanine to cysteine) and a change in charge in a highly conserved region involved in SV40 large T antigen binding (5, 12) . In another child with B cell precursor ALL, whose p53 mutation was hereditary, a codon in this same region, codon 272, was abnormal (GTG to TTG, valine to leucine). Although these specific mutations have not been observed in other cancers, many mutations cluster in regions of the gene conserved in evolution and it has been speculated that they disrupt the regulatory interaction of p53 with a putative cellular counterpart of large T (15, 17, 18, 19, 22) .
The lymphoblasts ofanother child with relapsed B-cell precursor ALL showed a nonhereditary homo-or hemizygous 2-bp deletion at p53 codons 214/215. The resultant frame shift and premature termination in exon 6 shortens the length ofthe p53 protein product by 44% and eliminates two of the evolutionarily conserved domains, one ofthe two SV40 large T antigen binding sites, and the nuclear localization signal (5, 12, 43) . This mutation in exon 6 may also have changed the conformation of the DNA and thus the accessibility of target sequences and/or splice junctions downstream, as a unique mRNA was identified which contained both the codon 214/215 deletion and a 133-bp insertion alternatively spliced between exons 9 and 10. This alternatively spliced p53 mRNA is distinct from any previously described (16, 17) because it arose by splicing a region which was already flanked at its 5' end in wild-type form by the 5'-ag-3' sequence ofa splice acceptor and thus began 196 bp internal to the start of the 2.5-kb intron 9. No mutation in intron 9 favoring alternative splicing was found. The intron 9 sequence at the 3' insertion/intron boundary (5'-gtaagt-3') may be a better splice donor consensus than that normally found at the exon 9/intron 9 boundary (5'-gtacta-3') (41). This 5'-gtaagt-3' may contain a common polymorphism which results in alternative splicing in that it was also found in genomic DNA from several normal individuals. In the leukemic cells with a more 5' termination codon in exon 6 the insertion in the p53 ORF is inconsequential (Fig. 2) . However, the same insertion contains an inframe TGA 82 bp downstream that would eliminate exons 10 and 11 from the reading frame and 62 amino acids from the p53 protein if present alone. The alternatively spliced mRNA may also reflect incomplete processing or an undetermined abnormality in transcriptional regulation.
Despite the early age ofan infant with B cell precursor ALL, the p53 codon 248 mutation observed at relapse was also nonhereditary and, moreover, presumably acquired at some time during the course of or perhaps as a result of therapy. This mutation would cause an amino acid substitution (arginine to proline) at a residue of the protein known to be abnormal in some individuals with the Li-Fraumeni syndrome. This residue again falls in a conserved region of p53 involved in murine SV40 large T antigen binding (5, 12) . The refractory nature of the disease ofthis infant at relapse may attest to the importance of a putative regulatory function (15, (17) (18) (19) 22) .
Findings of loss of heterozygosity are often suggestive of mutations in tumor suppressor genes. In the heritable form of retinoblastoma, for example, a small mutation in one allele is usually germline and precedes the loss of the second allele in tumor cells (3, 44 (50, 5 1) . By two independent screening tests, this study indicates that the frequency of p53 mutations in childhood ALL is relatively low (4 of 25) . This low frequency is in contrast to mutations reported in 5 of 10 T cell ALL cell lines where in vitro selection has been suggested (52) . However, this low frequency of detectable mutations does not preclude involvement of p53 by other mechanisms including transcriptional inactivation or posttranslational modification.
We also searched for the presence of germline p53 mutations and examined medical and family histories for cancers characteristic ofthe Li-Fraumeni syndrome (42) . The Li-Fraumeni family which we identified differs from others reported to have hereditary p53 mutations in both the range of tumors which occurred (childhood ALL, osteogenic sarcoma, and lung cancer) and the codon 272 location ofthe germline p53 mutation. This point mutation is also in contrast to major structural rearrangements of the p53 gene which have been described in osteogenic sarcoma (21) . These findings predict that additional heterogeneity in tumor types and specific mutations will be found as additional Li-Fraumeni families are investigated.
The pedigree of another child with B cell precursor ALL also seems consistent with a cancer-prone family, having two other cases of childhood leukemia and leukemia and other cancers over four generations of adults. The p53 codon 214/ 215 deletion which was found, nonetheless, was nonhereditary and occurred in a region ofthe gene distinct from that involved in previously reported Li-Fraumeni families. Moreover, in two other patients where ALL represented a second cancer, no p53 mutation was identified at all. These data suggest that a p53 mutation may not always be inherited or even present in certain cancer-prone individuals and that a mutant gene other than p53 may be inherited in families with multiple members affected by leukemia. Thus, in childhood ALL variant cancer susceptibility syndromes and a more multifactorial pathogenetic process are possible.
